Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Novel Drug Targets Two Kidney Injury Conditions

 
• By Andrew McConaghie
  
Kidneys
Vifor is on the hunt for new licensing deals, especially in nephrology, where it aims to be a market leader.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip